Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2020
Date Filed: March 27, 2020
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural report regarding regulatory cleansing rather than a financial statement.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The document focuses on regulatory compliance items rather than operational or financial performance changes.
Guidance, Outlook, and Management Commentary
Regulatory Action: The filing addresses "Appendix 2A and Section 708A(5) Cleansing" under Australian regulations.
Registration Statements: This Form 6-K is incorporated by reference into the company's Registration Statement on Form S-8 (File No. 333-228671) and Registration Statements on Form F-3 (Files No. 333-220886 and 333-231417).
Management Commentary: No specific outlook, risks, or contingencies regarding business operations are detailed in the provided text.
Investor Verification Checklist
- Verify the status of the "Appendix 2A and Section 708A(5) Cleansing" referenced in Item 99.1.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for details on capital raising or equity plans.
- Confirm the company's financial position by consulting the most recent Form 20-F or quarterly reports, as this 6-K contains no financial data.